Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $48.20

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned a consensus rating of "Buy" from the seven ratings firms that are covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $48.20.

OTLK has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Thursday, August 15th. Chardan Capital reissued a "buy" rating and issued a $53.00 target price on shares of Outlook Therapeutics in a report on Friday, August 16th. Finally, Ascendiant Capital Markets lowered their price target on shares of Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, September 3rd.

Insider Buying and Selling

In related news, CFO Lawrence A. Kenyon acquired 5,000 shares of the business's stock in a transaction on Thursday, September 26th. The stock was acquired at an average cost of $5.69 per share, with a total value of $28,450.00. Following the acquisition, the chief financial officer now directly owns 5,946 shares in the company, valued at $33,832.74. This represents a 500.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OTLK. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Outlook Therapeutics during the 2nd quarter worth approximately $303,000. AQR Capital Management LLC purchased a new stake in Outlook Therapeutics during the second quarter valued at $75,000. Squarepoint Ops LLC purchased a new stake in Outlook Therapeutics during the second quarter valued at $232,000. Great Point Partners LLC lifted its position in Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock valued at $12,557,000 after purchasing an additional 221,510 shares during the last quarter. Finally, LVW Advisors LLC purchased a new position in shares of Outlook Therapeutics in the 2nd quarter worth $352,000. Institutional investors own 11.20% of the company's stock.

Outlook Therapeutics Price Performance

Shares of OTLK traded down $0.02 during trading hours on Friday, hitting $5.23. The stock had a trading volume of 254,947 shares, compared to its average volume of 357,112. The firm has a market capitalization of $122.41 million, a PE ratio of -0.46 and a beta of 0.62. Outlook Therapeutics has a 12 month low of $4.40 and a 12 month high of $18.00. The stock has a fifty day moving average price of $6.86 and a 200 day moving average price of $7.67.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.23. As a group, analysts anticipate that Outlook Therapeutics will post -3.59 EPS for the current fiscal year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.